Please wait while the formulary information is being retrieved.
Drug overview for ZEVTERA (ceftobiprole medocaril):
Generic name: CEFTOBIPROLE MEDOCARIL (SEF-toe-BYE-prole)
Drug class: Beta-Lactams
Therapeutic class: Anti-Infective Agents
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: CEFTOBIPROLE MEDOCARIL (SEF-toe-BYE-prole)
Drug class: Beta-Lactams
Therapeutic class: Anti-Infective Agents
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for ZEVTERA (ceftobiprole medocaril) have been approved by the FDA:
Indications:
Community acquired bacterial pneumonia
Escherichia coli pneumonia
Haemophilus parainfluenza pneumonia
Klebsiella pneumonia
Right-sided Staphylococcus aureus endocarditis
Staphylococcal septicemia
Staphylococcus aureus skin and skin structure infection
Professional Synonyms:
Bacterial community acquired pneumonia
Community acquired pneumonia due to bacteria
E. coli pneumonia
Pneumonia due to E. coli
Pneumonia due to Escherichia coli
Pneumonia due to Haemophilus parainfluenzae
Pneumonia due to Hemophilus parainfluenzae
Pneumonia due to Klebsiella species
Pneumonia due to Klebsiella spp.
Septicemia due to Staphylococcus species
Septicemia due to Staphylococcus spp.
Skin and skin soft tissue Staphylococcus aureus infection
Staphylococcal sepsis
Indications:
Community acquired bacterial pneumonia
Escherichia coli pneumonia
Haemophilus parainfluenza pneumonia
Klebsiella pneumonia
Right-sided Staphylococcus aureus endocarditis
Staphylococcal septicemia
Staphylococcus aureus skin and skin structure infection
Professional Synonyms:
Bacterial community acquired pneumonia
Community acquired pneumonia due to bacteria
E. coli pneumonia
Pneumonia due to E. coli
Pneumonia due to Escherichia coli
Pneumonia due to Haemophilus parainfluenzae
Pneumonia due to Hemophilus parainfluenzae
Pneumonia due to Klebsiella species
Pneumonia due to Klebsiella spp.
Septicemia due to Staphylococcus species
Septicemia due to Staphylococcus spp.
Skin and skin soft tissue Staphylococcus aureus infection
Staphylococcal sepsis
The following dosing information is available for ZEVTERA (ceftobiprole medocaril):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| ZEVTERA 667 MG VIAL | Maintenance | Adults infuse 667 mg by intravenous route every 8 hours |
No generic dosing information available.
The following drug interaction information is available for ZEVTERA (ceftobiprole medocaril):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
There are 0 moderate interactions.
The following contraindication information is available for ZEVTERA (ceftobiprole medocaril):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 7 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min |
| Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min |
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
| Clostridioides difficile infection |
| Lower seizure threshold |
| Seizure disorder |
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for ZEVTERA (ceftobiprole medocaril):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 14 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Abnormal hepatic function tests Hyponatremia |
| Rare/Very Rare |
|---|
|
Agranulocytosis Anaphylaxis Anemia Asthma Clostridioides difficile infection Eosinophilia Hypokalemia Leukopenia Renal failure Seizure disorder Thrombocytopenic disorder Thrombocytosis |
There are 31 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Diarrhea Hyperbilirubinemia Hypertension Injection site sequelae Nausea Vomiting |
Dizziness Dysgeusia Fever Headache disorder Phlebitis after infusion Skin rash |
| Rare/Very Rare |
|---|
|
Acute abdominal pain Agitation Candidiasis Drowsy Dyspepsia Dysphagia Dyspnea Fatigue Hyperglycemia Hypertriglyceridemia Hypocalcemia Insomnia Muscle spasm Nightmares Panic disorder Peripheral edema Pruritus of skin Sore throat Symptoms of anxiety |
The following precautions are available for ZEVTERA (ceftobiprole medocaril):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for ZEVTERA (ceftobiprole medocaril):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ZEVTERA (ceftobiprole medocaril)'s list of indications:
| Community acquired bacterial pneumonia | |
| J13 | Pneumonia due to streptococcus pneumoniae |
| J14 | Pneumonia due to hemophilus influenzae |
| J15.0 | Pneumonia due to klebsiella pneumoniae |
| J15.20 | Pneumonia due to staphylococcus, unspecified |
| J15.211 | Pneumonia due to methicillin susceptible staphylococcus aureus |
| J15.29 | Pneumonia due to other staphylococcus |
| J15.5 | Pneumonia due to escherichia coli |
| Escherichia coli pneumonia | |
| J15.5 | Pneumonia due to escherichia coli |
| Haemophilus parainfluenza pneumonia | |
| J15.6 | Pneumonia due to other gram-negative bacteria |
| Klebsiella pneumonia | |
| J15.0 | Pneumonia due to klebsiella pneumoniae |
| Right-sided s. aureus endocarditis | |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| B95.61 | Methicillin susceptible staphylococcus aureus infection as the cause of diseases classified elsewhere |
| B95.62 | Methicillin resistant staphylococcus aureus infection as the cause of diseases classified elsewhere |
| I33.0 | Acute and subacute infective endocarditis |
| I33.9 | Acute and subacute endocarditis, unspecified |
| Staphylococcal septicemia | |
| A41.0 | Sepsis due to staphylococcus aureus |
| A41.01 | Sepsis due to methicillin susceptible staphylococcus aureus |
| A41.02 | Sepsis due to methicillin resistant staphylococcus aureus |
| A41.1 | Sepsis due to other specified staphylococcus |
| A41.2 | Sepsis due to unspecified staphylococcus |
| P36.2 | Sepsis of newborn due to staphylococcus aureus |
| P36.3 | Sepsis of newborn due to other and unspecified staphylococci |
| P36.30 | Sepsis of newborn due to unspecified staphylococci |
| P36.39 | Sepsis of newborn due to other staphylococci |
| Staphylococcus aureus skin and skin structure infection | |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.02 | Furuncle of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.12 | Furuncle of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.22 | Furuncle of trunk |
| L02.221 | Furuncle of abdominal wall |
| L02.222 | Furuncle of back [any part, except buttock and flank] |
| L02.223 | Furuncle of chest wall |
| L02.224 | Furuncle of groin |
| L02.225 | Furuncle of perineum |
| L02.226 | Furuncle of umbilicus |
| L02.229 | Furuncle of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.32 | Furuncle of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.42 | Furuncle of limb |
| L02.421 | Furuncle of right axilla |
| L02.422 | Furuncle of left axilla |
| L02.423 | Furuncle of right upper limb |
| L02.424 | Furuncle of left upper limb |
| L02.425 | Furuncle of right lower limb |
| L02.426 | Furuncle of left lower limb |
| L02.429 | Furuncle of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.52 | Furuncle hand |
| L02.521 | Furuncle right hand |
| L02.522 | Furuncle left hand |
| L02.529 | Furuncle unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.62 | Furuncle of foot |
| L02.621 | Furuncle of right foot |
| L02.622 | Furuncle of left foot |
| L02.629 | Furuncle of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.82 | Furuncle of other sites |
| L02.821 | Furuncle of head [any part, except face] |
| L02.828 | Furuncle of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.92 | Furuncle, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| N48.22 | Cellulitis of corpus cavernosum and penis |
Formulary Reference Tool